Navigation Links
Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors
Date:1/8/2009

rg> Foundation. He has previously served as a Commissioner of the NJ Commission on Science and Technology. Dr. Barer received a Ph.D. in Organic Chemistry from Rutgers University.

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera for the treatment of Gaucher disease and AT2220 for the treatment of Pompe disease.

FOLD-G


'/>"/>
SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Amicus Therapeutics to Present at Lazard Capital Markets Healthcare Conference
2. Amicus Therapeutics Announces Third Quarter 2008 Financial Results
3. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
4. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
5. Amicus Therapeutics Opens Research Facility in San Diego
6. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
7. Amicus Therapeutics Announces Second Quarter 2008 Results Release Date
8. Amicus Therapeutics Announces First Quarter 2008 Financial Results
9. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
Post Your Comments:
*Name:
*Comment:
*Email: